In the first activity of this CME Outfitters Snack series, expert faculty will provide learners with the opportunity to grow their knowledge and understanding of the clinical manifestations, transmission, and exposure risks of dengue disease.
Please join expert faculty in this recorded CMEO webcast as they discuss topics including early diagnosis, patient/caregiver QoL, team-based care, the role of pharmaceutical cannabinoid (CBD) in treatment, and regulatory guidelines. Through this discussion learners will become acquainted with improved tactics to diagnose and treat early-life seizures.
During this 30-minute CMEO Snack, Drs. Wechsler and Dua will identify best practices and current guidelines for the clinical evaluation and differential diagnosis of EGPA. Using a case presentation to frame the discussion, faculty will explain the differential diagnosis of EGPA as well as how to integrate diagnostic methods and interpret results.
Expert faculty will engage the audience in the development of improved skills in identifying the signs and symptoms of PI to reduce diagnostic delays, emphasize the importance of implementing consistent, guideline-directed treatment plans for all patients, and advise on the importance of effective patient-clinician communication and education.
In this educational webcast, expert faculty will discuss treatment needs of adult patients with SMA and the unique challenges and experiences of those patients transitioning from pediatric to adult care.
During this 90-minute enduring material, expert panelists will discuss biomarkers that identify patients at the pre-symptomatic phase of the disease and share knowledge about caring for patients with MLD.
During this 30-minute CMEO Snack, Dr. Gordon will join Dr. Michael Wechsler, a national expert in EGPA. They will discuss how EGPA impacts patient quality of life and how clinicians can better detect and manage hidden symptoms of disease.
During this CMEO Snack, Drs. Wechsler and Akuthota will use 3-D models to discuss the pathophysiology and clinical course of EGPA, including eosinophilic manifestations of the disease and the effect of anti-IL-5 therapy on eosinophil activity in EGPA.
During this 30-minute CMEO Snack, Drs. Wechsler and Seo will discuss how to integrate EGPA treatments, including IL-5 targeted therapies, based on current treatment guidelines and patient-specific factors.